282 related articles for article (PubMed ID: 26047999)
1. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
3. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
Magee AG; Makhecha S; Bentley S
Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
[TBL] [Abstract][Full Text] [Related]
4. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA; Poon H
Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
[TBL] [Abstract][Full Text] [Related]
5. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
7. Oral Tadalafil in Children with Pulmonary Arterial Hypertension.
Shiva A; Shiran M; Rafati M; Zamani H; Babazadeh K; Saeedi M; Ala S
Drug Res (Stuttg); 2016 Jan; 66(1):7-10. PubMed ID: 25611962
[TBL] [Abstract][Full Text] [Related]
8. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
10. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
[TBL] [Abstract][Full Text] [Related]
11. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Kiliçkesmez K; Küçükoğlu MS
Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():16-8. PubMed ID: 20819751
[TBL] [Abstract][Full Text] [Related]
12. Tadalafil for the treatment of pulmonary arterial hypertension.
Klinger JR
Expert Rev Respir Med; 2011 Jun; 5(3):315-28. PubMed ID: 21702653
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
Sabri MR; Bigdelian H; Hosseinzadeh M; Ahmadi A; Ghaderian M; Shoja M
Cardiol Young; 2017 Nov; 27(9):1686-1693. PubMed ID: 28994364
[TBL] [Abstract][Full Text] [Related]
14. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
15. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates.
Poitras EL; Gust SL; Kerr PM; Plane F
Curr Med Chem; 2021; 28(12):2418-2437. PubMed ID: 32964819
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
[TBL] [Abstract][Full Text] [Related]
18. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Chrysant SG
Curr Hypertens Rep; 2013 Oct; 15(5):475-83. PubMed ID: 23917809
[TBL] [Abstract][Full Text] [Related]
20. Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Ried M; Neu R; Lehle K; Großer C; Szöke T; Lang G; Hofmann HS; Hoenicka M
Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):254-259. PubMed ID: 28486684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]